Cover Image

PAPERBACK
$65.00



View/Hide Left Panel

Townsend, J., and Nanchahal, K. (2005). Hormone replacement therapy: Limited response in the UK to the new evidence. British Journal of General Practice, 55(516), 555.

Vaupel, J. (2003). The future of human longevity: How important are markets and innovation? Testimony before the Senate Special Committee on Aging. Science of Aging Knowledge Environment, (26), 18.

Vrablik, M., Fait, T., Kovar, J., Poledne, R., and Ceska, R. (2008). Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism: Clinical and Experimental, 57(8), 1088-1092.

Waaseth, M., Bakken, K., and Lund, E. (2009). Patterns of hormone therapy use in the Norwegian Women and Cancer Study (NOWAC) 1996-2005. Maturitas, 63(3), 220-226.

Women’s Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701-1712.

Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 288(3), 321-333.

Wysowski, D.K., and Governale, L.A. (2005). Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiology and Drug Safety, 14, 171-176.

Wysowski, D.K., Golden, L., and Burke, L. (1995). Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstetrics and Gynecology, 85(1), 6-10.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement